Sign in
CompletedNo phase

Bleeding Risk With Apixaban Versus Rivaroxaban in Acute Pulmonary Embolism

Key facts

Who runs it
Combined military hospital lahore
Where
Pakistan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
540 people enrolled
Started
1 Jan 2021
Ended
15 Feb 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Drug: Apixaban
  • Drug: Rivaroxaban
Record updated
24 August 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • CT pulmonary angiography-confirmed acute PE
  • Intraluminal pulmonary arterial filling defect

Who cannot take part

  • Previous major bleeding
  • Hemophilia or other bleeding disorder
  • Active bleeding
  • Known platelet disorder
  • Creatinine clearance < 30 mL/min
  • Pregnancy or lactation
  • Indication for therapeutic anticoagulation other than VTE

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This prospective, open-label, randomized controlled trial will compare clinically relevant bleeding during the first three months of treatment with apixaban versus rivaroxaban in adults with acute pulmonary embolism (PE) in a Pakistani cohort. A total of 540 participants will be randomized 1:1 to receive standard acute-treatment regimens of either apixaban or rivaroxaban. The primary outcome will be the composite of major bleeding or clinically relevant non-major (CRNM) bleeding within three months, defined according to International Society on Thrombosis and Haemostasis (ISTH) criteria.

The 2 groups in the trial

  • ApixabanTreatment being tested

    Participants will receive 10 mg twice daily for 7 days, then 5 mg twice daily for 3 months total

    Treatment: Drug: Apixaban

  • RivaroxabanExisting treatment, for comparison

    Participants will receive 15 mg twice daily for 21 days, then 20 mg once daily for 3 months total

    Treatment: Drug: Rivaroxaban

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Bleeding Risk With Apixaban Versus Rivaroxaban in Acute Pulmonary Embolism: A Single-Center Randomized Controlled Trial in Pakistan
Record updated
24 August 2026